Sarah M. Derks

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real-World Study.

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real-World Study.

Journal: International journal of cancer

Published: March 19, 2026

A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies.

A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies.

Journal: Clinical immunology (Orlando, Fla.)

Published: December 29, 2025

Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study.

Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study.

Journal: PloS one

Published: December 03, 2025

Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study.

Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study.

Journal: Therapeutic advances in medical oncology

Published: October 08, 2025

Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real-world matched comparison of overall survival.

Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real-world matched comparison of overall survival.

Journal: International journal of cancer

Published: April 23, 2025

Treatment and survival of patients with esophageal and gastric cancer in the Netherlands and Belgium: A population-based comparison.

Treatment and survival of patients with esophageal and gastric cancer in the Netherlands and Belgium: A population-based comparison.

Journal: International journal of cancer

Published: February 13, 2025

Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe: A Strategy Proposed by the LEGACy Consortium.

Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe: A Strategy Proposed by the LEGACy Consortium.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: February 01, 2025

Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project.

Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project.

Journal: ESMO open

Published: November 23, 2024

Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study.

Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 03, 2024

Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence.

Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence.

Journal: British journal of cancer

Published: October 01, 2024

Gastric cancer hospital-based registry: real-world gastric cancer data from Latin America and Europe.

Gastric cancer hospital-based registry: real-world gastric cancer data from Latin America and Europe.

Journal: ESMO gastrointestinal oncology

Published: September 18, 2024

Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands.

Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands.

Journal: EClinicalMedicine

Published: September 11, 2024

Showing 1-12 of 71

Last Updated: 09/26/2026